Chrome Extension
WeChat Mini Program
Use on ChatGLM

Diagnostic Accuracy of a Mobile AI-Based Symptom Checker and a Web-Based Self-Referral Tool in Rheumatology: Multicenter Randomized Controlled Trial

Materials & Design(2024)SCI 1区

Institute for Digital Medicine | Friedrich Alexander Univ Erlangen Nurnberg | Univ Grenoble Alpes | Verein Forderung Rheumatol eV | RheumaDatenRhePort Rhadar

Cited 0|Views15
Abstract
BackgroundThe diagnosis of inflammatory rheumatic diseases (IRDs) is often delayed due to unspecific symptoms and a shortage of rheumatologists. Digital diagnostic decision support systems (DDSSs) have the potential to expedite diagnosis and help patients navigate the health care system more efficiently. ObjectiveThe aim of this study was to assess the diagnostic accuracy of a mobile artificial intelligence (AI)–based symptom checker (Ada) and a web-based self-referral tool (Rheport) regarding IRDs. MethodsA prospective, multicenter, open-label, crossover randomized controlled trial was conducted with patients newly presenting to 3 rheumatology centers. Participants were randomly assigned to complete a symptom assessment using either Ada or Rheport. The primary outcome was the correct identification of IRDs by the DDSSs, defined as the presence of any IRD in the list of suggested diagnoses by Ada or achieving a prespecified threshold score with Rheport. The gold standard was the diagnosis made by rheumatologists. ResultsA total of 600 patients were included, among whom 214 (35.7%) were diagnosed with an IRD. Most frequent IRD was rheumatoid arthritis with 69 (11.5%) patients. Rheport’s disease suggestion and Ada’s top 1 (D1) and top 5 (D5) disease suggestions demonstrated overall diagnostic accuracies of 52%, 63%, and 58%, respectively, for IRDs. Rheport showed a sensitivity of 62% and a specificity of 47% for IRDs. Ada’s D1 and D5 disease suggestions showed a sensitivity of 52% and 66%, respectively, and a specificity of 68% and 54%, respectively, concerning IRDs. Ada’s diagnostic accuracy regarding individual diagnoses was heterogenous, and Ada performed considerably better in identifying rheumatoid arthritis in comparison to other diagnoses (D1: 42%; D5: 64%). The Cohen κ statistic of Rheport for agreement on any rheumatic disease diagnosis with Ada D1 was 0.15 (95% CI 0.08-0.18) and with Ada D5 was 0.08 (95% CI 0.00-0.16), indicating poor agreement for the presence of any rheumatic disease between the 2 DDSSs. ConclusionsTo our knowledge, this is the largest comparative DDSS trial with actual use of DDSSs by patients. The diagnostic accuracies of both DDSSs for IRDs were not promising in this high-prevalence patient population. DDSSs may lead to a misuse of scarce health care resources. Our results underscore the need for stringent regulation and drastic improvements to ensure the safety and efficacy of DDSSs. Trial RegistrationGerman Register of Clinical Trials DRKS00017642; https://drks.de/search/en/trial/DRKS00017642
More
Translated text
Key words
symptom checker,artificial intelligence,eHealth,diagnostic decision support system,rheumatology,decision support,decision,diagnostic,tool,rheumatologists,symptom assessment,resources,randomized controlled trial,diagnosis,decision support system,support system,support
求助PDF
上传PDF
Bibtex
AI Read Science
AI Summary
AI Summary is the key point extracted automatically understanding the full text of the paper, including the background, methods, results, conclusions, icons and other key content, so that you can get the outline of the paper at a glance.
Example
Background
Key content
Introduction
Methods
Results
Related work
Fund
Key content
  • Pretraining has recently greatly promoted the development of natural language processing (NLP)
  • We show that M6 outperforms the baselines in multimodal downstream tasks, and the large M6 with 10 parameters can reach a better performance
  • We propose a method called M6 that is able to process information of multiple modalities and perform both single-modal and cross-modal understanding and generation
  • The model is scaled to large model with 10 billion parameters with sophisticated deployment, and the 10 -parameter M6-large is the largest pretrained model in Chinese
  • Experimental results show that our proposed M6 outperforms the baseline in a number of downstream tasks concerning both single modality and multiple modalities We will continue the pretraining of extremely large models by increasing data to explore the limit of its performance
Upload PDF to Generate Summary
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Related Papers
Université Grenoble Alpes, AGEIS, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, RheumaDatenRhePort (rhadar), Klinik für Internistische Rheumatologie, Rhein-Maas Klinikum, University of Grenoble Alpes & Orange Labs, Fricker Achim, Sozialstiftung Bamberg,MVZ für Rheumatologie Dr. Martin Welcker GmbH
2021

被引用49 | 浏览

Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn
Chat Paper

要点】:本研究评估了基于移动人工智能的症状检查器Ada和基于网络的自我推荐工具Rheport在诊断炎症性风湿病(IRDs)中的准确性,发现两者准确性不高,指出数字诊断决策支持系统(DDSSs)需要严格监管和显著改进以确保其安全性和有效性。

方法】:研究采用前瞻性、多中心、开放标签、交叉随机对照试验设计,在三个风湿病中心的新就诊患者中进行。

实验】:600名患者参与实验,随机使用Ada或Rheport进行症状评估,实验结果以风湿科医生的诊断为金标准。结果显示Rheport对IRDs的建议准确性为52%,Ada的前1名(D1)和前5名(D5)疾病建议的准确性分别为63%和58%。在个别诊断中,Ada的准确性表现不一,对于诊断类风湿关节炎的表现明显优于其他诊断。两个DDSSs在风湿病诊断上的一致性较差。